Third Quarter 2025 Financial Results Conference Call October 30, 2025 Forward-looking statements Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "projec ...

Financial Performance - Apellis reported approximately $151 million in GA (Geographic Atrophy) revenue for 2Q 2025[10] - EMPAVELI U S net product sales were $208 million in 2Q 2025[18] - SYFOVRE U S net product sales were $1506 million in 2Q 2025[18] - The company received $275 million upfront from a royalty purchase agreement for 90% of future ex-U S royalties for Aspaveli[17] - Total revenue for 2Q 2025 was $1785 million, compared to $1997 million in 2Q 2024[18] EMPAVELI and Pipeline - EMPAVELI received U S FDA approval for C3G and primary IC-MPGN[10] - Apellis plans to initiate pivotal studies in DGF (Delayed Graft Function) and FSGS (Focal Segmental Glomerulosclerosis) by year end[10, 21] - APL-3007 reduced circulating C3 concentration by up to 90% in a Phase 1 healthy volunteer study[25] SYFOVRE - SYFOVRE's overall GA market share exceeds 60%[10] - Apellis initiated a Phase 2 study of SYFOVRE + APL-3007[10, 23] Market and Strategy - Approximately 5,000 C3G and primary IC-MPGN patients are estimated in the U S [28, 29] - The company aims to raise awareness about EMPAVELI as a disease-modifying therapy and establish it as the treatment of choice for relevant conditions[33, 34]